

Supplementary materials

Circulating and local nuclear expression of survivin and fibulin-3 genes in discriminating benign from malignant respiratory diseases: Correlation analysis

Running title: Survivin and fibulin-3 in respiratory diseases

**Mohammed H. Hassan^{1,*} Sawsan Abuhamdah^{2,3} Mohamed Abdel-Bary⁴,
Mohammed Wahman⁵, Tarek Hamdy Abd-Elhamid⁶, Morris Beshay⁷, Karam
Mosallam⁴, Bakheet E.M. Elsadek⁸**

¹Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.

²College of Pharmacy, Al Ain University, Abu Dhabi, UAE.

³Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.

⁴Department of Cardio-Thoracic Surgery, Faculty of Medicine, South Valley University, Qena, Egypt.

⁵Department of Oncology and Nuclear Medicine, Faculty of Medicine, South Valley University, Qena, Egypt.

⁶Department of Histology and Cell Biology, Faculty of Medicine, Assiut University, Assiut, Egypt.

⁷Department of General Thoracic Surgery, Protestant Hospital of Bethel Foundation, Burgsteig 13, Bielefeld, Germany.


⁸Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, 71524 Assiut, Egypt.

Corresponding author: *To whom correspondence should be addressed:


Dr. Mohammed H. Hassan, Associate Professor of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.

E-mail: Mohammedhosnyhassaan@yahoo.com;

mohammedhosnyhassaan@med.svu.edu.eg; Tel.: +201098473605



Supplementary Figure1. Full uncropped and unedited versions of the western blots for survivin expression (A): First run; (B) second run; (C): third run; (D) β -actin; from patients with various benign and malignant respiratory diseases to assure the reproducibility of results. BL, benign lung diseases; BP, benign pleural diseases; ML, malignant lung diseases; MP, malignant pleural diseases.



Supplementary Figure 2. Full uncropped and unedited versions of the western blots for fibulin-3 expression (A): First run; (B) second run; (C): third run; (D) β -actin; from patients with various benign and malignant respiratory diseases to assure the reproducibility of results. BL, benign lung diseases; BP, benign pleural diseases; ML, malignant lung diseases; MP, malignant pleural diseases.